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Table 1 Number of Chemotherapy Response Associated SNPs
and Their MAF Distribution
Drug/Treatment N, SNPs MAF min-max
Doxorubicin and
Vincristine
28 0.05-0.49
Rituximab 14 0.05-0.44
Cladribine 2 0.10-0.28
Interferon alfa-2a 13 0.28-0.46
Asparaginase 2 0.24-0.46
Abstractsauto-HSCT. The conditioning regimens had acceptable toxicity.
Complications grade 3-4 were observed in 36% of cases after the
ﬁrst HDCT and in 24% cases after the second HDCT. The main
complications were severe mucositis, infections and hepatotoxicity.
Two-year overall survival (OS) in all patient’s group was 70% and
disease free survival (DFS) was 59%. DFS rate of patients who had
received tandem HDCT was 65%, while all patients who had
received only the ﬁrst auto-HSCT died (8 e due to disease pro-
gression, 1 e after acute neurological complication). Patients in CR
at the moment of HDCT had better DFS rate than patients in PR:
75% and 51% (p¼0,043), respectively. Conclusions: tandem
HDCT with auto-HSCT in pediatric patients with high-risk CNS
tumors may be a feasible option for patients in CR or PR after
induction chemotherapy. It has an acceptable toxicity.RES-086
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Primary chemotherapy drug resistance is a one of the major issues
of medical hematology-oncology affecting about 20% of all patients.
In Armenia, clinical data suggest that the rate of primary resistance
depends on the disease and treatment type and varies in the range of
10-30%. One of the mechanisms of resistance is a drug inactivation
mediated by metabolizing enzymes and it has been known that the
variability of those genes contributes to the response to drugs and
treatment efﬁcacy. In Armenia a number of drugs are used for
treatment acute and chronic hematology-oncological diseases, such
as doxorubicin and vincristine (leukemia or lymphoma), rituximab
(lymphoma), cladribine (hairy cell leukemia), interferon alfa-2a
(chronic myeloid leukemia) and asparaginase (acute lymphoblastic
leukemia). However, the distribution of genetic polymorphisms that
modulate response to the above mentioned drugs in unknown in
Armenians. In this study we were aimed at performing pilot char-
acterization of distribution of single nucleotide polymorphisms
affecting chemotherapy treatment response in Armenian
population.
We used genome wide genotyping data of 168 healthy Arme-
nians from three freely available datasets used in population genetics
studies. 112 single nucleotide polymorphisms (SNPs) interfering
the mentioned treatment agents were obtained from PharmgKB
database. The distribution of allele frequencies in Armenians was
compared to the allelic rates in European population available in
1000 Genomes and HapMap project (retrieved using LDLink
software).
Minor allele frequency (MAF) associated with altered response to
drugs (Table 1) varied in the range of MSD: 0.250.14, mini-
mum-maximum: 0.00-0.49. The minor allele frequency of 18 SNPs
was signiﬁcantly higher in Armenians compared with European
population. Another 18 SNPs were signiﬁcantly underrepresentedin Armenians. Six SNPs (MAF min-max: 0.22-0.48) were associ-
ated with the altered response to 5 and more drugs.
Our preliminary results demonstrate the overall enrichment of
genetic factors connected to the risk of failure and toxicity of
chemotherapy in Armenian population and necessitate the further
research on their cumulative impact on the chemotherapy response
in patients with blood cancers.RES-092
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Background/Objectives: Adverse neurological events are com-
mon (4-20%) during treatment for pediatric acute lymphoblastic
leukaemia (ALL) and include seizures, stroke like syndrome and
leukoencephalopathy. In addition, chronic neurotoxicity is
emerging as a worrying late effect of treatment with long-term
survivors experiencing decreased executive function, processing
speed and memory function. Survivors are also at increased risk of
experiencing learning difﬁculties, social withdrawal issues and
inattention hyperactivity disorders. Methotrexate, an anti-folate
chemotherapy agent, is a mainstay of pediatric leukemia treatment
regimens globally and is widely implicated as a cause of these
neurological side effects. We hypothesise that methotrexate disrupts
DNA methylation via effects on S-adenosyl methionine, a key
metabolic component that has previously been described to regulate
genes involved in myelination. Design/Methods: Using both the
oligodendrocytic-like cell line MO3.13 and glial cells derived from
induced pluripotent stem cells (iPSC) treated with methotrexate, we
assayed for changes in DNA methylation and effects on gene
expression using whole-genome methylation arrays and RNAseq,
respectively. Genes with corresponding methylation and expressionClinical Lymphoma, Myeloma & Leukemia September 2017 - S385
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S386changes were selected for further studies of expression by real-time
qPCR and assessment of protein levels. Results: We identiﬁed
DNA methylation and corresponding expression changes in genes
involved in neurodevelopmental pathways and neurological disor-
ders. Of particular interest was dose-dependent demethylation and
increased gene expression of IRS1, a vital component of insulin
signalling pathways that is highly expressed in neural tissue and
implicated in regulating cognitive performance. We also detected
altered DNA methylation within the PLP1 gene, which encodes the
most prevalent protein component of myelin. We found that
methotrexate treatment in iPSC-derived oligodendrocytes resulted
in increased PLP1 methylation associated with a reduction in PLP1
transcript levels as well as PLP1 protein levels. Conclusions: Our
work provides insight as to the biological mechanisms behind
methotrexate-induced neurological side effects for the ﬁrst time and
implicates altered insulin signalling and myelination pathways as a
potential causative factor in neurotoxicity. Further work including
the use of animal models is warranted for advancing these results
towards informing clinical practice.
The authors would like to thank the JGW Paterson Foundation,
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Context: Febrile neutropenia is a relatively frequent event among
cancer patients treated with chemotherapy. Since these patients lack
the appropriate immunologic response, early recognition and
empiric treatment is crucial. Objective: This study was conducted
in order to determine the outcome and mortality rate of febrile
neutropenia in patients admitted to a university hospital during one
year, and to evaluate the accuracy of management. Methods: An
epidemiologic, prospective study was conducted at the hematology-
oncology unit at Notre Dame de Secours University hospital from
September 2015 until December 2016. All adult patients admittedTable 1 Multivariate Analysis
Variable Odds ratio 95% C
Previous NF episode 1.47 0.307
Moribund 3.677 1.2
Hypotension 5.609 1.711
Previous fungal infection 1.905 0.407
Uncontrolled disease 4.222 1.019
The prognostic score ranged from 0 (best prognosis) to 7.5 (worst prognosis). Cut-off value of 4.5
- Clinical Lymphoma, Myeloma & Leukemia September 2017to the hospital with the diagnosis of febrile neutropenia were
included. A statistical analysis was conducted to identify factors
related to poor outcome and overall mortality rate. Results: Median
age at the onset of febrile neutropenia was 61 years with a female
predominance (64.7%). At diagnosis, 23 patients were already
hospitalized (45.09%) and 28 were outpatients (54.9%). Patients
were divided according to the MASCC score into three categories
47.1% mild, 31.4% moderate and 21.6% severe neutropenia.
50.98% of patients were found to have solid tumors while 49.01%
had hematologic malignancies.
In 66.7% of the cases the causative germ was not identiﬁed;
cultures grew Staph epi in 13.8%, followed by E.coli in 9.9% of the
cases.
6 patients passed away (11.8%), 4 of them died from a septic
choc, and one patient died of candidemia. All 6 patients were
classiﬁed as severe by the MASCC score and they were well treated.
Conclusion: Our study demonstrated that the overall mortality rate
in our institution is comparable to international centers. In most
cases, no germ is identiﬁed in cultures which justify the usage of
broad spectrum antibiotics. The initial choice of antibiotics in our
institution meets the international recommendations.RES-096
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Context: Predicting the response to treatment for NF is critical in
patients with hematological malignancy. Objective: To evaluate
different risk factors affecting treatment outcome. Design: A pro-
spective observational study includes patients with haematological
malignancies who presented to NEMROCK. Study conducted
between 1st of June 2014 till the end of October 2015. Setting:
This study demonstrated new risk factors to be considered in he-
matological malignant patients. Patients or other participants: All
adult patients with hematological malignancies presented to
NEMROCK with a NF attacks were included in the study. A total
142 patients suffered from 270 NF episodes. Interventions: Ac-
cording to the MASCC score, high risk patients were treated in-
patients. All admitted patients were subjected to blood cultureI P value WPS
7.023 0.63 –
11.265 0.023 2
18.392 0.004 3
8.91 0.413 –
17.493 0.047 2.5
was determined and it divides patients into two groups, 4.5 vs. >4.5
